SCHEMBL3437173

SCHEMBL3437173

CC(=O)Oc1ccc(OC(C)=O)c(C=O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.53
MAPT P10636 2/20 0.47
MAPK1 P28482 1/20 0.47
LMNA P02545 4/20 0.46
CYP3A4 P08684 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
TTR P02766 1/20 0.45
TP53 P04637 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 3/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
BACE1 P56817 1/20 0.44
ACHE P22303 1/20 0.44
GAA P10253 3/20 0.43
ERN1 O75460 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4644522 0.90 ALDH1A1 (0.59) KDM4EMAPTLMNAKMT2AMEN1
SCHEMBL3829716 0.87 KDM4E (0.59) KDM4EMAPTMAPK1LMNACYP3A4
SCHEMBL7029122 0.85 KDM4E (0.48) KDM4EMAPK1LMNAKMT2AMEN1
SCHEMBL8350638 0.83 KDM4E (0.47) KDM4EMAPTMAPK1LMNACYP3A4
SCHEMBL3437174 0.83 KDM4E (0.47) KDM4EMAPTMAPK1LMNACYP3A4
SCHEMBL3437175 0.83 KDM4E (0.47) KDM4EMAPTMAPK1LMNACYP3A4
SCHEMBL6703981 0.82 CYP3A4 (0.44) KDM4EMAPTCYP3A4ALDH1A1RAB9A
SCHEMBL21807289 0.82 ALDH1A1 (0.47) KDM4EMAPTALDH1A1RAB9AGAA
SCHEMBL11464187 0.82 SRC (0.47) KDM4ELMNASMN1; SMN2ALDH1A1RAB9A
SCHEMBL10774506 0.82 ERN1 (0.66) KDM4EMAPTLMNACYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013114040-A1 NOVEL COMPOUNDS AND COMPOSITIONS USED AS ANTICANCER AGENTS UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) 2013-08-08 WO disclosed
US-20100331549-A1 Novel compounds useful for modulating abnormal cell proliferation ROIFMAN CHAIM 2010-12-30 US disclosed
US-7807719-B2 Compounds useful for modulating abnormal cell proliferation Roifman, Chaim (CA) 2010-10-05 US disclosed
EP-1797064-A4 NOVEL COMPOUNDS USEFUL FOR MODULATING ABNORMAL CELL PROLIFERATION HOSPITAL FOR SICK CHILDREN (CA) 2009-06-24 EP disclosed
EP-1797064-A1 NOVEL COMPOUNDS USEFUL FOR MODULATING ABNORMAL CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2007-06-20 EP disclosed
WO-2006029515-A1 NOVEL COMPOUNDS USEFUL FOR MODULATING ABNORMAL CELL PROLIFERATION THE HOSPITAL FOR SICK CHILDREN (CA) 2006-03-23 WO disclosed
US-20060058297-A1 4-Chloro-2-cyano-5-phenyl-penta-2E,4Z-dienoic acid 3,4-dihydroxybenzylamide, used as antiproliferative agents THE HOSPITAL FOR SICK CHILDREN 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058297-A1 4-Chloro-2-cyano-5-phenyl-penta-2E,4Z-dienoic acid 3,4-dihydroxybenzylamide, used as antiproliferative agents MKI67, CCNA2, CDK4 KDM4E 279/4885MAPT 4694/4885MAPK1 1789/4885
US-20100331549-A1 Novel compounds useful for modulating abnormal cell proliferation MKI67, CALU, CDK4 KDM4E 3729/4885MAPT 2662/4885MAPK1 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.